Twist Bioscience Corporation (TWST)

NMS – Real Time Price. Currency in USD

55.95

-0.26 (-0.46%)

At close: May 12, 2026, 4:00 PM EDT

56.01

+0.06 (0.11%)

Pre-market: May 13, 2026, 4:12 AM EDT

08.05.2026

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

DÜSSELDORF, Germany--(BUSINESS WIRE)--LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will integrate our ALiCE® platform with Twist's DNA manufacturing and automation capabilities to accelerate the design–build–test cycle for protein expression services—delivering experimental results back to customers' and partners' AI models faster. “AI can design n.

07.05.2026

Twist Bioscience: AI Momentum Is Real, But The Easy Money Has Been Made

Twist Bioscience (TWST) delivered strong Q2 results, driven by AI-enabled drug discovery. NGS growth was soft due to a demand air pocket caused by a large customer. Growth is expected to rebound as this company's commercial test volumes ramp. Twist's fundamentals are likely to continue improving in coming quarters. Growth investments will create modest near-term margin headwinds though.

05.05.2026

These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results

Twist Bioscience Corporation (NASDAQ:TWST) on Monday reported a loss for its fiscal 2026 second quarter.

05.05.2026

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units (“RSUs”) and up to 13,348 performance stock units (“PSUs”), will be granted to 53 recently hired individuals, in each case as an inducement material to their acceptance of employment w.

04.05.2026

Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript

04.05.2026

AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens

Twist Bioscience Corporation (NASDAQ:TWST) shares are down on Monday as the company reported its fiscal 2026 second-quarter financial results.

04.05.2026

Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates

Twist Bioscience (TWST) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.66 per share a year ago.

Videos

No Data

There is no data to display

Press releases

08.05.2026

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

05.05.2026

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

04.05.2026

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes. “As research in nucleic acid therapeutics and AI-guided protein design and therapeutics discovery accelerate, scientists need a reliable partner to consistently deliver genes rapidly at scale and with more complex sequences,” said Emily M. Leproust, Ph.D., CEO and co-founder.

04.05.2026

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal second quarter 2026 earnings report and the investor presentation, or click https://investors.tw.

Twist Bioscience Corporation (TWST)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Twist Bioscience Corporation (TWST)

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Twist Bioscience: AI Momentum Is Real, But The Easy Money Has Been Made

These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript

AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens

Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates

Videos

No Data

Press releases

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Twist Bioscience: AI Momentum Is Real, But The Easy Money Has Been Made

These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript

AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens

Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates

Videos

No Data

Press releases

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

Search stocks

Twist Bioscience Corporation (TWST)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Twist Bioscience Corporation (TWST)

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Twist Bioscience: AI Momentum Is Real, But The Easy Money Has Been Made

These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript

AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens

Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates

Videos

No Data

Press releases

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Twist Bioscience: AI Momentum Is Real, But The Easy Money Has Been Made

These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript

AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens

Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates

Videos

No Data

Press releases

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results